Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
A much-needed focus on progression in multiple sclerosis.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Limit cycle oscillations in standing human posture.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Genzyme provides update on U.S. LEMTRADA™ filing
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Extension CombiRx data show no benefit of combined MS drugs
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Mitoxantrone-related acute leukemia in MS: An open or closed book?

Pages